BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34937269)

  • 1. Harada-like syndrome post-Covishield vaccination: A rare adverse effect.
    Reddy Y; Pandey A; Ojha A; Ramchandani S
    Indian J Ophthalmol; 2022 Jan; 70(1):321-323. PubMed ID: 34937269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
    Rujkorakarn P; Patamatamkul S
    J Fr Ophtalmol; 2023 Mar; 46(3):207-210. PubMed ID: 36775731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.
    de Queiroz Tavares Ferreira F; Araújo DC; de Albuquerque LM; Bianchini PM; Holanda EC; Pugliesi A
    Ocul Immunol Inflamm; 2023 Aug; 31(6):1134-1140. PubMed ID: 35914285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vogt Koyanagi Harada syndrome in a 15-year-old girl, steroids side effects and recurrences.
    Yıldırım G; Çavdarlı C; Özdemir EY; Alp MN
    Turk J Pediatr; 2021; 63(3):527-532. PubMed ID: 34254501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
    De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
    Accorinti M; Saturno MC; Manni P
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine.
    Kim SY; Kang MS; Kwon HJ
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1218-1221. PubMed ID: 35113750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
    Joo CW; Kim YK; Park SP
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
    Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
    Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
    Madoe A; Schauwvlieghe PP; Jacob J
    Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
    Xu K; Gao B; Li J; Xiang Y; Cao L; Zhao M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2220630. PubMed ID: 37282614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
    Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
    Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vogt-Koyanagi-Harada
    Campos WR; Cenachi SPF; Soares MS; Gonçalves PF; Vasconcelos-Santos DV
    Ocul Immunol Inflamm; 2021 Jan; 29(1):124-127. PubMed ID: 31603703
    [No Abstract]   [Full Text] [Related]  

  • 14. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
    Kikuchi R; Kawagoe T; Hotta K
    BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vogt-Koyanagi-Harada Disease Associated with Hepatitis B Vaccination.
    Sood AB; O'Keefe G; Bui D; Jain N
    Ocul Immunol Inflamm; 2019; 27(4):524-527. PubMed ID: 29953303
    [No Abstract]   [Full Text] [Related]  

  • 16. Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
    Ushio R; Yamamoto M; Miyasaka A; Muraoka T; Kanaoka H; Tamura H; Kaneko A; Izawa A; Hirama N; Teranishi S; Manabe S; Inoue T; Shibata K; Sugiura Y; Kudo M; Kaneko T
    Intern Med; 2021 Nov; 60(22):3593-3598. PubMed ID: 34092725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma.
    Apivatthakakul A; Kunavisarut P; Rothova A; Pathanapitoon K
    Ocul Immunol Inflamm; 2020 Apr; 28(3):505-508. PubMed ID: 31161956
    [No Abstract]   [Full Text] [Related]  

  • 18. [Vitiligo revealing Vogt -Koyanagi-Harada disease].
    Amraoui ME; Zemmez Y; Bouhamidi A; Frikh R; Hjira N; Boui M
    Pan Afr Med J; 2017; 27():220. PubMed ID: 28979622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India.
    Martin TD; Rathinam SR; Cunningham ET
    Retina; 2010; 30(7):1113-21. PubMed ID: 20168275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine.
    Koong LR; Chee WK; Toh ZH; Ng XL; Agrawal R; Ho SL
    Ocul Immunol Inflamm; 2021 Aug; 29(6):1212-1215. PubMed ID: 34505819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.